Condition
Immune System Disorders
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT01002742Phase 3Completed
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
NCT00224874Phase 2Completed
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
NCT03351543Phase 1CompletedPrimary
Effect of Microbial Exposure on Health, Particularly Immune System
Showing all 3 trials